Company Overview and News

‘Buy’ for bank stocks following Q1 sell-off

7h bworldonline
THE GROWTH of banking stocks slowed during the quarter as market volatility sent investors into profit-taking mode despite the sector’s good earnings reports. For this quarter, however, most analysts interviewed have signaled a “buy” on the sector amid expectations of better earnings in the months ahead.

Yields on gov’t securities drop on thin trading

7h bworldonline
DOMESTIC BOND yields fell on thin trading after the Bangko Sentral ng Pilipinas (BSP) trimmed bank reserve requirements by one percentage point, and amid stronger chances of a US rate hike in June.

Of millennials and banking

7h bworldonline
AT TIMES, finding time to do mundane tasks such as paying bills or transferring funds to loved ones could be challenging. In doing so, one has to line up in kilometric lines in banks or payment centers, resulting in foregone time that could have been spent on doing something else.

Players look for signals amid Q1 market volatility

7h bworldonline
UNCERTAINTY may once again be the theme for 2018 as developments at home and abroad in the first quarter sent local financial markets on a spin.

Can consumers keep on availing of car loans amid TRAIN?

7h bworldonline
BANKS HAVE BEEN lending out more readily to consumers, offering promos and flexible payment schemes to entice first-time buyers or even those wanting to buy a second car. This ease of credit, coupled with households’ increasing disposable incomes, have led to the increasing share of car loans into the banks’ loan portfolios over the years.

Faster spending growth widens 4-month deficit

2018-05-23 bworldonline
THE GOVERNMENT’S deficit grew nearly fourfold in the four months to April from a year ago as a hike in state spending outstripped that of revenue collections, the Finance chief said on Wednesday, even as the fiscal gap still fell short of program.

RCBC net income up 13% in 1st quarter

2018-05-11 bworldonline
RIZAL Commercial Banking Corp. (RCBC) reported its net income went up 13% in the first quarter supported by robust loan growth and reduction in non-performing assets.

RCBC books higher Q1 profit on strong loan growth

2018-05-11 bworldonline
Rizal Commercial Banking Corp. (RCBC) reported higher net profit in the first quarter supported by robust loan growth and reduction in non-performing assets.

Weak trade data add to growth risks

2018-05-09 bworldonline
THE Philippine economy — whose first-quarter performance will be reported today — could not rely on trade as sales abroad of locally made products shrank for the third straight month last March.

BSP closes 2 more money changers

Bank regulators have revoked the licenses of two more money changers caught violating provisions of the country’s law against the traffic of dirty money.

BSP shuts down two more money changers for AMLA violations

Bank regulators revoked the licenses of two more money changers reportedly caught violating Philippine law against “dusty money.”

The Billion-Dollar Bank Job - The New York Times

2018-05-08 nytimes
In 2016, a mysterious syndicate tried to steal $951 million from Bangladesh’s central bank - and laid bare a profound weakness in the system by which money moves around the world.

Economic growth picks up in Q1 — poll

2018-05-07 bworldonline
ECONOMISTS expect economic growth to pick up pace in the first quarter on the back of higher household and consumer spending that would largely offset the effects of inflation and the wider trade deficit.

Central bank likely to hike key rates

2018-05-06 bworldonline
THE BANGKO SENTRAL ng Pilipinas (BSP) may raise interest rates this week after nearly four years of staying on hold, with inflation hitting five-year highs and showing slim signs of slowing over the coming months, analysts said in a BusinessWorld poll.

PH not privy to Bangladesh-RCBC plan

The Philippine government has “nothing to do” with a statement by Bangladesh’s central bank that it is open to an out-of-court settlement with Rizal Commercial Banking Corp. (RCBC), Finance Secretary Carlos Dominguez said on Friday.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...